MetaVia (NASDAQ: MTVA) completes DA-1726 Phase 1 dose titration milestone
Rhea-AI Filing Summary
MetaVia Inc. reported a key operational milestone in its obesity program. All enrolled active patients in Part 3 of its Phase 1 trial of DA-1726 have completed dose titration and are now receiving their highest target doses of 48 mg and 64 mg in the two cohorts.
Part 3 includes two 16-week titration regimens designed to test one-step and two-step dose escalation, with about 40 obese but otherwise healthy adults randomized 4:1 to active drug versus placebo. The company reiterated that topline data from this Phase 1 Part 3 study remain on track for release in the fourth quarter of 2026.
MetaVia highlighted earlier Phase 1 multiple ascending dose results where DA-1726 produced 9.1% mean weight loss at the 48 mg dose over 8 weeks, along with improvements in waist circumference, glycemic control, and early liver signals, supporting the potential of its dual GLP-1/glucagon mechanism in obesity and related metabolic disease.
Positive
- None.
Negative
- None.
Insights
MetaVia hit a Phase 1 obesity trial milestone but key efficacy data still await Q4 2026.
MetaVia advanced DA-1726 by completing dose titration in all active Part 3 Phase 1 subjects, with patients now at 48 mg and 64 mg target doses. This shows the titration schemes can reach higher exposure levels that may be relevant for maximal efficacy, while management characterizes tolerability as favorable.
The trial’s design, with roughly 40 obese adults randomized 4:1 per part and two 16-week regimens, should generate a richer safety and pharmacology dataset than earlier studies. Prior multiple ascending dose data, including 9.1% mean weight loss at 48 mg over 8 weeks, frame expectations but do not guarantee replication.
Investors will likely focus on the Q4 2026 topline from Part 3 for confirmation of weight-loss magnitude, cardiometabolic markers, and liver signals, given DA-1726’s dual GLP1R/GCGR mechanism and competition from existing GLP-1 and dual-agonist obesity therapies.
8-K Event Classification
Key Figures
Key Terms
dose titration clinical
multiple ascending dose (MAD) clinical
treatment-emergent adverse events (TEAEs) clinical
pharmacokinetics (PK) clinical
Metabolic Dysfunction-Associated Steatohepatitis (MASH) medical
G-protein-coupled receptor 119 (GPR119) medical
FAQ
What did MetaVia (MTVA) announce about its DA-1726 Phase 1 obesity trial?
What doses are being tested in MetaVia’s DA-1726 Phase 1 Part 3 study?
When is MetaVia expecting topline data from the DA-1726 Phase 1 Part 3 trial?
How many subjects are planned for MetaVia’s DA-1726 Phase 1 Part 3 obesity trial?
What weight loss results has DA-1726 shown in earlier MetaVia studies?
What conditions is MetaVia targeting with DA-1726 and vanoglipel?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) |
(Zip Code) |
(
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 7.01 | Regulation FD Disclosure. |
On July 9, 2026, MetaVia Inc. (the “Company”) issued a press release announcing that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity (the “Phase 1 Trial”) have successfully completed dose titration and are now receiving their highest target doses in both study cohorts, and that topline data from the Phase 1 Trial is on track to be released in the fourth quarter of 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated herein by reference.
Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only.
The information in Item 7.01 of this Report, including Exhibit 99.1 attached hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
| Item 8.01 | Other Events. |
On July 9, 2026, the Company provided an update on its ongoing Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity, reporting that all enrolled active patients in the trial have successfully completed dose titration and are now receiving their highest target doses of 48 mg and 64 mg in both study cohorts. The Company is still planning to release the data readout for Part 3 of its Phase 1 clinical trial evaluating DA-1726 in the fourth quarter of 2026.
Forward-Looking Statements
This Report, including Exhibit 99.1 attached hereto, contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports that the Company has filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit Number |
Exhibit Description | |
| 99.1 | Press Release dated July 9, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MetaVia Inc. | ||
| Date: July 9, 2026 | By: | /s/ Hyung Heon Kim |
| Hyung Heon Kim | ||
| President and Chief Executive Officer | ||
Exhibit 99.1
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg
Topline Data Remains on Track for Fourth Quarter 2026
CAMBRIDGE, Mass., July 9, 2026 – MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed dose titration and are now receiving their highest target doses in both study cohorts. DA-1726 is a novel oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. Part 3 of the Phase 1 program consists of two 16-week titration cohorts designed to evaluate one-step and two-step dose-escalation strategies to safely achieve higher target doses and further optimize tolerability. In Part 3A, patients titrated from 16 mg to 48 mg, while in Part 3B, patients titrated from 16 mg to 32 mg and subsequently to 64 mg.
“The successful completion of dose titration across both Part 3 cohorts represents an important milestone for the DA-1726 development program,” stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. “Reaching our highest planned dose levels in all active patients reinforces the favorable tolerability profile of DA-1726. We believe our efficient titration strategy could represent a meaningful competitive advantage over currently marketed obesity therapies.”
Mr. Kim continued, “The robust data from our previously reported Phase 1 MAD study, including 9.1% mean weight loss achieved at the 48 mg dose in just 8 weeks of treatment, meaningful reductions in waist circumference, improved glycemic measures, and early signs of direct liver benefit, continue to demonstrate the differentiated potential of our dual GLP-1/glucagon mechanism. With all patients now on their target doses, we remain focused on completing treatment and reporting topline data in the fourth quarter of 2026.”
The Phase 1 Part 3 trial has a planned enrollment of approximately 40 obese, otherwise healthy adult subjects, across two parts, with approximately 20 subjects per part, randomized 4:1 (16 active; 4 placebo). Part 3A is designed to evaluate a one-step titration regimen with 16 mg for 4 weeks followed by 48 mg for 12 weeks, while Part 3B will evaluate a two-step titration regimen with 16 mg for 4 weeks, 32 mg for 4 weeks, and 64 mg for 8 weeks. The study will assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726. Primary endpoints include monitoring adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs leading to treatment discontinuation. Secondary and exploratory endpoints include PK profiling and evaluation of metabolic, glycemic, lipid, and body composition measures, including weight, waist circumference, and body mass index (BMI), and other cardiometabolic measures.
For more information on this clinical trial, please visit: www.clinicaltrials.gov NCT06252220.
About DA-1726
DA-1726 is a novel GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in preclinical mice models, resulted in improved weight loss compared to semaglutide (Wegovy®), a leading GLP-1 receptor agonist. Additionally, in preclinical mouse models, DA-1726 elicited similar weight reduction, while consuming more food, compared to tirzepatide (Zepbound®) and survodutide (a drug with the same MOA), while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide. In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a potential first-in-class drug candidate targeting G-protein-coupled receptor 119 (GPR119). In preclinical studies, vanoglipel demonstrated a positive metabolic effect on glucose and lipid control, and also proved differentiated hepatic benefits reducing hepatic steatosis, hepatic inflammation, and liver fibrosis regardless independent of metabolic improvement. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", “potential”, "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia’s ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of preclinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com